Embracing a Challenge: Breast Cancer Expert Pushes Forward After Much Success
April 12th 2013An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.
Numerous Drug Classes Studied for Use in Follicular Lymphoma
April 9th 2013Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.
Baselga Recaps Research Into Three Breast Cancer Pathways
April 9th 2013José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.
Interferon Therapy: A Growing Family Feeds New Interest in an Older Treatment
April 1st 2013Interferons have evolved from a "cure-all" for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of different disease states, including many different types of cancer.
Rethinking Overall Survival: Still an Acceptable Sole Primary Endpoint in Cancer Clinical Trials?
March 29th 2013A clinical commentary by Maurie Markman, MD, addressing whether overall survival can still be considered the sole acceptable primary endpoint in studies of novel anticancer therapeutic strategies.
AGS-003 Vaccine Achieves Survival Benefits in mRCC
March 26th 2013AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.